Ocugen reports 31% lesion reduction in gene therapy trial

March 24, 2026 7:45 AM

Ocugen Inc. (NASDAQ: OCGN) announced 12-month results from its Phase 2 ArMaDa clinical trial testing OCU410 gene therapy for geographic ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found